4 rows
125 mg via Oral (flexible)
Reported in 4 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
MDMA clinical studies for PTSD include 26 structured dose rows across 18 linked trials. Common source-reported dose patterns include 125 mg, 25 mg, 80-180 mg. Interpret these as descriptive trial protocols, not treatment recommendations.
This page summarizes source-structured dosing used in linked human clinical studies. It preserves the source-reported unit, route, frequency, and regimen notes where available.
Patterns group structured dose rows with the same reported dose, route, and regimen type. They preserve source units and do not imply clinical equivalence.
Reported in 4 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 2 dose rows. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Reported in 1 dose row. Source rows retain their original units and should be read descriptively, not as dosing guidance.
Routes: Oral
Each row comes from a linked clinical trial intervention. Rows with missing or reviewed-incomplete dosing stay visible instead of being filled by inference.
| Study | Arm | Dose | Route and regimen | Source status |
|---|---|---|---|---|
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) | MDMA-assisted therapy MDMA | 80-180 mg | Oral | flexible three sessions | 3 doses Initial 80 or 120 mg followed 1.5–2 h later by supplemental half-dose (40 or 60 mg); per-session total 80–180 mg. | Not reviewed existing-data | mdma-assisted-therapy-for-severe-ptsd-a-randomized-double-blind-placebo-controll |
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) | MDMA-assisted therapy MDMA | 80-180 mg | Oral | flexible three sessions | 3 doses Initial 80–120 mg followed 1.5–2 h later by a supplemental half-dose (40 or 60 mg); three monthly experimental sessions. | Not reviewed existing-data | mdma-assisted-therapy-for-moderate-to-severe-ptsd-a-randomized-placebo-controlle |
A Test of MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder | MDMA-AT MDMA | 125 mg | Oral | multi-dose two sessions | 2 doses Supplemental 62.5 mg 2–2.5 h after initial dose. | Not reviewed existing-data | the-safety-and-efficacy-of-34-methylenedioxymethamphetamine-assisted-psychothera |
Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls | MDMA MDMA | 100 mg | Oral | fixed single dose | 1 dose Absolute dose 100 mg (~1.3 ± 0.3 mg/kg) administered in gelatin capsule with mannitol. | Not reviewed existing-data | oxytocin-in-response-to-mdma-provocation-test-in-patients-with-arginine-vasopres |
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD | MDMA 100 mg MDMA | 100 mg | Oral | flexible two sessions | 2 doses Optional supplemental half-dose (50 mg) 1.5–2.5 h after initial dose. | Not reviewed existing-data | 34-methylenedioxymethamphetamine-assisted-psychotherapy-for-treatment-of-chronic |
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD | MDMA 125 mg MDMA | 125 mg | Oral | flexible two sessions | 2 doses Optional supplemental half-dose (62.5 mg) 1.5–2.5 h after initial dose. | Not reviewed existing-data | 34-methylenedioxymethamphetamine-assisted-psychotherapy-for-treatment-of-chronic |
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD | MDMA 40 mg MDMA | 40 mg | Oral | flexible two sessions | 2 doses Optional supplemental half-dose (20 mg) 1.5–2.5 h after initial dose. | Not reviewed existing-data | 34-methylenedioxymethamphetamine-assisted-psychotherapy-for-treatment-of-chronic |
Drug Effects on Interpersonal Interaction | MDMA vs placebo MDMA | 100 mg | Oral single dose | 1 dose Single 100 mg oral MDMA session; order counterbalanced. | Not reviewed existing-data | drug-induced-social-connection-both-mdma-and-methamphetamine-increase-feelings-o |
Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD | MDMA-assisted therapy MDMA | Not reported | Oral per session 30, 75, or 125 mg oral MDMA followed 1.5–2 h later by a supplemental half-dose (dose condition per parent trial). | Not reviewed evidence-for-altered-neural-activity-patterns-after-mdma-assisted-therapy-in-adu |
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD | MDMA + CBCT MDMA | 75-100 mg | Oral | flexible two sessions | 2 doses Session 1: 75 mg initial with optional supplemental 37.5 mg 1.5–2 h later. Session 2: initial 75 or 100 mg with optional supplemental 37.5 mg or 50 mg respectively. | Not reviewed existing-data | mdma-facilitated-cognitive-behavioural-conjoint-therapy-for-posttraumatic-stress |
MDMA-assisted Psychotherapy for Anxiety Associated With a Life-threatening Illness | MDMA-assisted therapy MDMA | 125-187.5 mg | Oral two sessions | 2 doses Optional supplemental dose 62.5 mg given 1.5–2.5 h after initial; open-label third session offered after unblinding. | Not reviewed existing-data | facing-death-returning-to-life-a-qualitative-analysis-of-mdma-assisted-therapy-f |
MDMA-assisted psychotherapy in the treatment of trauma | MDMA-assisted psychotherapy MDMA | 75-125 mg | Oral | flexible Monthly, 3 sessions total | 3 doses Supplemental dose of 50% the initial dose offered 90–120 min after initial administration (37.5 mg or 62.5 mg). Participants ultimately received total MDMA amounts of 112.5 mg and 187.5 mg across sessions. | Not reviewed existing-data | 34-methylenedioxymethamphetamine-mdma-assisted-psychotherapy-for-victims-of-sexu |
MDMA-Assisted Psychotherapy Low-Dose Pilot for Chronic PTSD: Double-Blind RCT (Bouso / Doblin / Farré, Madrid Spain 2000–2002) | MDMA 50mg MDMA | 50 mg | Oral | fixed single dose | 1 dose Administered in a psychotherapeutic setting with 6 psychotherapy sessions (3 before, 3 after). | Not reviewed existing-data | mdma-assisted-psychotherapy-using-low-doses-in-a-small-sample-of-women-with-chro |
MDMA-Assisted Psychotherapy Low-Dose Pilot for Chronic PTSD: Double-Blind RCT (Bouso / Doblin / Farré, Madrid Spain 2000–2002) | MDMA 75mg MDMA | 75 mg | Oral | fixed single dose | 1 dose Administered in a psychotherapeutic setting with 6 psychotherapy sessions (3 before, 3 after). | Not reviewed existing-data | mdma-assisted-psychotherapy-using-low-doses-in-a-small-sample-of-women-with-chro |
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD | MDMA-assisted therapy MDMA | 80-180 mg | Oral three sessions | 3 doses Initial 80–120 mg with 40–60 mg supplemental 1.5–2 h later; total per session 80–180 mg. | Not reviewed existing-data | mdma-assisted-therapy-is-associated-with-a-reduction-in-chronic-pain-among-peopl |
Open-Label Proof of Concept Feasibility Study to Explore the Safety, Tolerability and Potential Role of MDMA-Assisted Psychotherapy for the Treatment of Detoxified Patients with Alcohol Use Disorder | MDMA-assisted psychotherapy MDMA | 62.5 mg | Oral per dosing session Capsule strength 62.5 mg (IMP specification). | Not reviewed existing-data | first-study-of-safety-and-tolerability-of-34-methylenedioxymethamphetamine-assis |
Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers | MDMA MDMA | 120-160 mg | Oral single dose 120 mg initial oral MDMA; supplemental 40 mg may be given 1.5–2.5 hours later; sessions in crossover design. | Not reviewed existing-data | mdma-assisted-therapy-for-posttraumatic-stress-disorder-a-mixed-methods-case-stu |
Randomized, Double-blind, Active Placebo-Controlled Pilot Study of MDMA-assisted Psychotherapy in People With Chronic PTSD | Active placebo (25 mg) MDMA | 25 mg | Oral two sessions | 2 doses Initial 25 mg with optional supplemental 12.5 mg 1.5–2.5 hours later; adjunct to psychotherapy. | Not reviewed existing-data | discontinuation-of-medications-classified-as-reuptake-inhibitors-affects-treatme |
Randomized, Double-blind, Active Placebo-Controlled Pilot Study of MDMA-assisted Psychotherapy in People With Chronic PTSD | Full dose (125 mg) MDMA | 125 mg | Oral | flexible two sessions | 2 doses Initial 125 mg with optional supplemental 62.5 mg 1.5–2.5 hours later; adjunct to psychotherapy. | Not reviewed existing-data | discontinuation-of-medications-classified-as-reuptake-inhibitors-affects-treatme |
Randomized, Double-blind, Active Placebo-Controlled Pilot Study of MDMA-assisted Psychotherapy in People With Chronic PTSD | Open‑label lead‑in MDMA | 125 mg | Oral | flexible two sessions | 2 doses Initial 125 mg with optional supplemental 62.5 mg 1.5–2.5 hours later; two experimental psychotherapy sessions (open‑label lead‑in). | Not reviewed existing-data | discontinuation-of-medications-classified-as-reuptake-inhibitors-affects-treatme |
Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD | MDMA-assisted therapy MDMA | 125 mg | Oral split dose per session | 2 doses 125 mg initial followed by 62.5 mg supplemental per experimental session; two blinded sessions in Stage 1; optional open-label third session after unblinding. | Not reviewed existing-data | discontinuation-of-medications-classified-as-reuptake-inhibitors-affects-treatme |
Study Comparing Three Doses of MDMA Along With Psychotherapy in Veterans With Posttraumatic Stress Disorder | Full dose MDMA | 125 mg | Oral single dose | 2 doses Supplemental half-dose (62.5 mg) 1.5–2.5 h after initial; receives a third open-label experimental session. | Not reviewed existing-data | 34-methylenedioxymethamphetamine-mdma-assisted-psychotherapy-for-post-traumatic- |
Study Comparing Three Doses of MDMA Along With Psychotherapy in Veterans With Posttraumatic Stress Disorder | Low dose MDMA | 30 mg | Oral single dose | 2 doses Supplemental half-dose (15 mg) 1.5–2.5 h after initial; two blinded sessions; may enter open-label crossover with three sessions. | Not reviewed existing-data | 34-methylenedioxymethamphetamine-mdma-assisted-psychotherapy-for-post-traumatic- |
Study Comparing Three Doses of MDMA Along With Psychotherapy in Veterans With Posttraumatic Stress Disorder | Medium dose MDMA | 75 mg | Oral single dose | 2 doses Supplemental half-dose (37.5 mg) 1.5–2.5 h after initial; two blinded sessions; may enter open-label crossover. | Not reviewed existing-data | 34-methylenedioxymethamphetamine-mdma-assisted-psychotherapy-for-post-traumatic- |
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder | Full dose MDMA MDMA | 125 mg | Oral | flexible three sessions | 3 doses 125 mg initial dose each session; optional 62.5 mg booster ~2.5 h after initial dose if agreed. | Not reviewed existing-data | a-randomized-controlled-pilot-study-of-mdma-34-methylenedioxymethamphetamine-ass |
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder | Low (active placebo) MDMA MDMA | 25 mg | Oral three sessions | 3 doses 25 mg initial dose each session; optional 12.5 mg booster ~2.5 h after initial dose if agreed. | Not reviewed existing-data | a-randomized-controlled-pilot-study-of-mdma-34-methylenedioxymethamphetamine-ass |